Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNK-UT001
- Development stage
- Phase 1
- Lead developer
- ST Phi Therapeutics
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
CNK-UT001 is an allogeneic T-cell therapy being developed by ST Phi Therapeutics for the treatment of hepatocellular carcinoma (HCC). The therapy is based on the company's proprietary CNK-UT platform, which involves engineering allogeneic T cells with a chimeric natural killer (NK) receptor. This chimeric receptor is designed to recognize NK cell receptor ligands that are frequently overexpressed on the surface of tumor cells. By binding to these ligands, the engineered T cells are activated to mediate the targeted elimination of the cancer cells. CNK-UT001 is currently in preclinical development and represents a novel approach to cell therapy by combining the potent effector functions of T cells with the broad tumor-recognition capabilities of NK cell receptors.
- Other names
- CNK-UT
02
Targets
MICB (Major histocompatibility complex class i-related protein B)NKp44L (NKp44 ligand)
Beyond the preview
Go deeper on CNK-UT001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNK-UT001.